FABP5’s role in tumor growth and migration was recently highlighted in the journal Science. Our drug candidate, ART26.12, is designed to shut down this cancer enabler and is the first #FABP5 #inhibitor to be administered to humans! News from Science #oncology

New in the journal Science! #FABP5 identified as a core lipid chaperone to support #cancer cell metabolism and survival. At $ARTL, we’re developing ART26.12—a selective inhibitor of FABP5— which disrupts cancer-enabling activity. News from Science science.org/doi/10.1126/sc…

$ARTL publishes new peer-reviewed research demonstrating ART26.12’s effectiveness in treating #Psoriasis. See the results here: jidonline.org/article/S0022-… #dermatology Journal of Investigative Dermatology

A recent Science paper drew attention to high expression of the protein #FABP5 in triple negative breast #cancer patients and is associated with their poor relapse-free survival. This points to the potential for $ARTL's ART26.12, the first selective FABP5 inhibitor to advance

An important research article in Science highlights FABP5’s role in lipid-driven cell proliferation in #cancer. A phase 1 study in healthy volunteers with ART26.12, a potent and selective inhibitor of #FABP5, is expected to conclude in May 2025. This is the first step on the path

FABP5, a promising and validated protein target to treat cancer and cancer treatment-associated morbidities, combines with a dietary fat to drive tumor growth. New research published in Science highlighted #FABP5’s role in #cancer and makes our research in the clinic with

$ARTL Provides Business Update and Reports First Quarter 2025 Financial Results ir.artelobio.com/news-events/pr…

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s #FABP Inhibitor Program in #Anxiety and #Depression $ARTL sciencedirect.com/science/articl…

$ARTL's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to #Naproxen in an #Osteoarthritis #Pain Study ir.artelobio.com/news-events/pr…

$ARTL Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain ir.artelobio.com/news-events/pr…

$ARTL Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model ir.artelobio.com/news-events/pr…

$ARTL Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium #ICRS2025 CannabinoidSociety ir.artelobio.com/news-events/pr…

$ARTL receives favorable UK MHRA guidance for a Phase 1 Trial of ART12.11, our proprietary CBD:TMP #cocrystal being developed for the treatment of #anxiety and #depression ir.artelobio.com/news-events/pr…

$ARTL Announces $9.475 Million At-the-Market Private Placement to Initiate #Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt #SOL as a Core Reserve Asset ir.artelobio.com/news-events/pr…

$ARTL Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 ir.artelobio.com/news-events/pr…

$ARTL Provides Business Update and Reports Second Quarter 2025 Financial Results ir.artelobio.com/news-events/pr…

$ARTL Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent #pain ir.artelobio.com/news-events/pr…

$ARTL Announces Positive Interim Phase 2 CAReS Results for the Treatment of #Cancer #Anorexia-Cachexia Syndrome (#CACS) ir.artelobio.com/news-events/pr…

$ARTL Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced #Depression and #Anxiety Symptoms ir.artelobio.com/news-events/pr…